NYSEAMERICAN:OSTX

OS Therapies (OSTX) Stock Price, News & Analysis

OS Therapies logo
$0.80 -0.02 (-2.12%)
Closing price 11/20/2026 04:10 PM Eastern
Extended Trading
$0.81 +0.01 (+0.87%)
As of 11/20/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About OS Therapies Stock (NYSEAMERICAN:OSTX)

Advanced

Key Stats

Today's Range
$0.79
▼
$0.86
50-Day Range
$0.68
▼
$1.83
52-Week Range
$0.58
▼
$2.25
Volume
489,729 shs
Average Volume
753,364 shs
Market Capitalization
$37.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33
Consensus Rating
Moderate Buy

Company Overview

OS Therapies is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare bone cancer, and potentially other cancers. Its work centers on therapies intended to address the significant risk of recurrence and spread associated with the disease.

The company’s lead candidate, OST-HER2, is an investigational immunotherapy designed to stimulate an immune response against HER2-expressing cancer cells. OS Therapies has studied it for osteosarcoma, including disease that has spread to the lungs. OST-HER2 remains an investigational product and is not an approved treatment.

OS Therapies also describes a broader development effort aimed at advancing treatments for osteosarcoma and other solid tumors. Its activities include clinical development and research into therapies for cancers with limited treatment options.

AI Generated. May Contain Errors.

OS Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

OSTX MarketRank™: 
1.780802694355 of 5 stars

OS Therapies scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OS Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    OS Therapies has a consensus price target of $13.33, representing about 1,560.4% upside from its current price of $0.80.

  • Amount of Analyst Coverage

    OS Therapies has received no research coverage in the past 90 days.

  • Read more about OS Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for OS Therapies are expected to grow in the coming year, from ($0.80) to $0.67 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OS Therapies is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OS Therapies is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    6.62% of the float of OS Therapies has been sold short.
  • Short Interest Ratio / Days to Cover

    OS Therapies has a short interest ratio ("days to cover") of 7.73.
  • Change versus previous month

    Short interest in OS Therapies has recently decreased by 2.15%, indicating that investor sentiment is improving.
  • Dividend Yield

    OS Therapies does not currently pay a dividend.

  • Dividend Growth

    OS Therapies does not have a long track record of dividend growth.

  • News Sentiment

    OS Therapies has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for OS Therapies this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for OSTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OS Therapies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.60% of the stock of OS Therapies is held by insiders.

  • Percentage Held by Institutions

    OS Therapies has minimal institutional ownership at this time.

  • Read more about OS Therapies' insider trading history.
Receive OSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OS Therapies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OSTX Stock News Headlines

OS Therapies (NYSEAMERICAN:OSTX) Shares Climb 9.4% - Still a Buy?
OS Therapies Notes FDA CNPV Program Suspension
Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More Headlines

OSTX Stock Analysis - Frequently Asked Questions

OS Therapies' stock was trading at $1.40 at the beginning of the year. Since then, OSTX shares have decreased by 42.6% and is now trading at $0.8030.

OS Therapies Incorporated (NYSEAMERICAN:OSTX) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.10.

OS Therapies' top institutional shareholders include State Street Corp (0.34%), Empowered Funds LLC (0.10%) and Sanders Morris Harris LLC (0.04%).
View institutional ownership trends
.

Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OS Therapies investors own include NVIDIA (NVDA), Archer Aviation (ACHR), BigBear.ai (BBAI), Joby Aviation (JOBY), Oklo (OKLO), Taiwan Semiconductor Manufacturing (TSM) and Super Micro Computer (SMCI).

Company Calendar

Last Earnings
11/16/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSEAMERICAN:OSTX
Previous Symbol
NYSE:OSTX
CIK
1795091
Fax
N/A
Employees
5
Year Founded
2018

Price Target and Rating

High Price Target
$20.00
Low Price Target
$7.00
Potential Upside/Downside
+1,560.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
1.20
P/E Growth
N/A
Net Income
-$28.75 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-544.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.08
Quick Ratio
0.18

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.37) per share
Price / Book
-2.17

Miscellaneous

Outstanding Shares
46,130,000
Free Float
41,698,000
Market Cap
$37.04 million
Optionable
N/A
Beta
-0.47

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NYSEAMERICAN:OSTX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners